During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
News|Videos|October 16, 2026
Chad Hatfield, Pharm.D., on the 340B uncertainty facing health systems| HSES 2026
Author(s)Lauren Gordon
Chad Hatfield, Pharm.D., of UC Davis Health, says 340B savings fund free clinics and mental health care that could shrink as the program’s future shifts.
Advertisement
The future of the
Hatfield described the program as stuck in a holding pattern, with open questions about whether it will move to a rebate model, whether legislation will change it and how cases moving through the courts will be resolved. “It’s a lot of hurry up and wait and anticipate,” he said. “We might go left field, we might go to right field, but ultimately we’re going to go to some field at some point in time.”
Asked about the biggest pain points, Hatfield said it is hard to single out one. “It’s really, really a death by 1,000 cuts, and it’s all coming down at the same time,” he said. Health systems, he added, are trying to navigate those pressures while building models of financial sustainability for their patients.
At UC Davis Health, 340B savings support a wide range of services, Hatfield said, including uncompensated care for patients who can’t pay their bills, mammography and colonoscopy for people who can’t afford them, free clinics and free drug programs. Much of that would shrink if the savings declined. He also pointed to mental health, which he said is not funded to the level the need demands. “A lot of those things are things that we pump money into in order to cover,” he said.
For patients, Hatfield said, the biggest concern is access to medications and a health system’s ability to dispense them so care stays coordinated within the system. Restrictions from both payers and manufacturers complicate that, he said, but most health systems are working their way through those access points.
In this video, Hatfield discusses where 340B may be headed and what is at stake for the patients health systems serve.
Advertisement
Related to this article
Fewer than 1 in 5 eligible adults get lung cancer screening. Experts told MHE over email that health plans can help by easing cost, coverage and approval barriers.
Healthcare spending for employer-insured Americans rose by nearly 19%between 2019 and 2023, driven by higher prices, surging drug costs, and spending on hospital care, says the president and CEO of the Health Care Cost Institute.
All 46 people with HIV who started long-acting lenacapavir and cabotegravir at a University of California, San Francisco, clinic reached or kept viral suppression over a median of 100 weeks.
Luis Garza, M.D., Ph.D., a Johns Hopkins professor, says hidradenitis suppurativa is neither an infection nor a classic autoimmune disease but an auto-inflammatory condition.
Vision impairment affected 17.6% of 1,484 adult burn survivors in a study presented at AAO 2026, with age the strongest predictor of difficulty seeing.
Hidradenitis suppurativa is becoming more common, and a Johns Hopkins expert suspects an unidentified chemical in processed foods may be one reason.
A two-year study of 53 glaucoma patients logged nearly 4,800 home VR visual field tests, yet no insurance code currently covers home perimetry.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Chronic hand eczema needs more than topical steroids | Fall Clinical Derm 2026
2
U.S. employer-covered healthcare costs: It’s still the prices
3
Choosing a first biologic for HS, as recommended by Jennifer Hsiao, M.D. | Fall Clinical Derm 2026
4
Pope Leo XIV's lung cancer diagnosis puts a spotlight on low U.S. screening rates
5